Hansa Biopharma AB (publ) (STO:HNSA)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 3.44B |
| Revenue (ttm) | 222.27M |
| Net Income (ttm) | -529.25M |
| Shares Out | 101.76M |
| EPS (ttm) | -6.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 296,792 |
| Average Volume | 444,726 |
| Open | 33.40 |
| Previous Close | 33.80 |
| Day's Range | 32.00 - 33.42 |
| 52-Week Range | 19.58 - 42.98 |
| Beta | 1.84 |
| RSI | 42.44 |
| Earnings Date | Feb 11, 2026 |
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoi... [Read more]
Financial Performance
In 2025, Hansa Biopharma AB's revenue was 222.27 million, an increase of 29.74% compared to the previous year's 171.32 million. Losses were -529.25 million, -34.44% less than in 2024.
Financial StatementsNews
Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
LUND, Sweden, Feb. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has be...
Hansa Biopharma AB (publ) (HNSBF) Q4 2025 Earnings Call Transcript
Hansa Biopharma AB (STU:24H) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ...
Hansa Biopharma AB (STU:24H) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Developments Amid Challenges
Q4 2025 Hansa Biopharma AB Earnings Call Transcript
Q4 2025 Hansa Biopharma AB Earnings Call Transcript
Hansa Biopharma AB (publ) 2025 Q4 - Results - Earnings Call Presentation
Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation.
Hansa Biopharma AB: Hansa Biopharma has won the 2025 SwedenBIO Award
LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award ...
Hansa Biopharma has won the 2025 SwedenBIO Award
LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award was ...
Hansa Biopharma AB at JPMorgan Healthcare Conference Transcript
Hansa Biopharma AB at JPMorgan Healthcare Conference Transcript
Hansa Biopharma AB (publ) (HNSBF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Hansa Biopharma AB: Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types of i...
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immu...
Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases - Slideshow
2025-11-12. The following slide deck was published by Hansa Biopharma AB (publ) in conjunction with this event.
Hansa Biopharma AB (publ) 2025 Q3 - Results - Earnings Call Presentation
Hansa Biopharma AB (publ) (HNSBF) Q3 2025 Earnings Call Transcript
Hansa Biopharma AB (HNSBF) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue ...
Hansa Biopharma AB (HNSBF) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue Challenges
Q3 2025 Hansa Biopharma AB Earnings Call Transcript
Q3 2025 Hansa Biopharma AB Earnings Call Transcript
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation. First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies...
Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
LUND, Sweden , Oct. 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Pro...
Hansa Biopharma AB (publ) Discusses on ConfIdeS US Phase 3 Pivotal Trial Topline Results Presentation
Hansa Biopharma AB (publ) - Special Call
Hansa Biopharma AB (publ) - Special Call Company Participants Renee Aguiar-Lucander - Chief Executive Officer Richard Philipson - Chief Medical Officer Monika Tornsen - COO & President of U.S. Angela ...
Hansa Biopharma AB (Publ) Discusses On ConfIdeS US Phase 3 Pivotal Trial Topline Results Call (Transcript)
Hansa Biopharma announces key executive appointments to support continued growth
LUND, Sweden , July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer and Cor...